THE MAIN MARKERS OF AUTOIMMUNE RHEUMATIC DISEASES AND THEIR INTERPRETATION
https://doi.org/10.20514/2226-6704-2016-6-5-5-11
Abstract
The aim of this work is to systematize of the data on markers of autoimmune rheumatic diseases. The article includes basic information taking the latest recommendations of 2014 into account. All pieces of material are presented in the form of tables for convenient use in daily practice of any specialist.
About the Authors
A. S. Burlakova
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
V. V. Vasilenko
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
D. L. Vinogradov
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
References
1. Allan S.W. et al. Cutting edge diagnostics in rheumatology: the Role of Patients, Clinicians, and Laboratory Scientists in Optimizing the Use of Autoimmune Serology. Arthritis & Rheumatism (Arthritis Care & Research). 2004; 51(2): 291–298.
2. Aleksandrova E.A., Novikov A.A. National recommendations for the laboratory diagnosis of rheumatic diseases. 2014; 48 p. [in Russian].
3. Meroni P.L., Biggioggero M., Pierangeli S.S., Sheldon J., et al. Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. NatureReviewsRheumatology. 2014; 10: 35–43.
4. Aletaha D.et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62: 2569–2581.
5. Hochberg M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40: 1725.
6. LeRoy E. C.et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 1988; 15: 202–205.
7. Shiboski S.C.et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res. 2012; 64: 475–487.
8. Amigues J.M., Cantagrel A., Abbal M. et al. Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse. J. Rheumatol. 1996; 23: 2055–2062.
9. Mosca M., Neri R., Bombardieri S.Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin. Exp. Rheumatol. 1999; 17: 615–620.
10. Miyakis S. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006; 4: 295–306.
11. Watts R. et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann. Rheum. Dis. 2007; 66: 222–227.
12. Nihtyanova S.I., Denton C.P. Autoantibodies as predictive tools in systemic sclerosis. Nat. Rev. Rheumatol. 2010; 6: 112–116.
13. Hirschfield G.M. Diagnosis of primary biliary cirrhosis. Best Pract. Res. Clin. Gastroenterol 2011; 25: 701–712.
14. Munoz L.E., Gaipl U.S., Herrmann M. Predictive value of anti-dsDNA autoantibodies: importance of the assay. Autoimmun. Rev. 2008; 7: 594–597.
15. Oke V., Wahren-Herlenius M. The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J. Autoimmun. 2012; 39: 77–82.
16. Mimori T., Imura Y., Nakashima R., Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr. Opin. Rheumatol. 2007; 19: 523–529.
17. Hanley J.G. et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis. Arthritis Rheum. 2008; 58: 843–853.
18. Katz U., Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun. Rev. 2010; 10: 46–50.
19. Gomez-Puerta J.A., Burlingame R.W., Cervera R. Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value. Autoimmun. Rev. 2008; 7: 606–611.
20. Pickering M.C., Botto M. Are anti-C1q antibodies different from other SLE autoantibodies. Nat. Rev. Rheumatol. 2010; 6: 490–493.
21. Willemze A., Trouw L.A., Toes R.E., Huizinga T.W. The influence of ACPA status and characteristics on the course of RA. Nat. Rev. Rheumatol. 2012; 8: 144–152.
Review
For citations:
Burlakova A.S., Vasilenko V.V., Vinogradov D.L. THE MAIN MARKERS OF AUTOIMMUNE RHEUMATIC DISEASES AND THEIR INTERPRETATION. The Russian Archives of Internal Medicine. 2016;6(5):5-11. (In Russ.) https://doi.org/10.20514/2226-6704-2016-6-5-5-11
Views:
1103
Email this article 